Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Three SHR4640 Tablet Formulations in Healthy Volunteers
NCT04586803Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of ruzinurad in hyperuricemia and gout (6 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Measurable Concentration and 1 more. Status: unknown.
02
Drugs
ruzinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT04586803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586803.